This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

The aim of this report is to assess the available information on the use of chondroitin sulfate for treatment of interstitial cystitis.

Chondroitin sulfate solution 2.0% is a glycosaminoglycan (GAG) replenishment therapy instilled into the bladder of GAG-deficient patients with interstitial cystitis (IC).

Two non-randomized, uncontrolled pilot studies report improvements in patient-reported symptoms after the use of chondroitin sulfate for one year. Prospective, randomized, head-to-head trials are needed to assess the effectiveness of this technology compared with other IC therapies.

The cost and demand for this technology are low, but there could be a significant impact on clinics that administer treatment, if uptake increases.